D-cycloserine added to clozapine for patients with schizophrenia

American Journal of Psychiatry

Volumn 153, Issue 12, 1996, Pages 1628-1630

  Goff, Donald C ^a   Tsai, Guochuan ^b   Manoach, Dara S ^b   Flood, James ^b   Darby, David G ^b   Coyle, Joseph T ^b  

^a Freedom Trail Clinic   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; CLOZAPINE DERIVATIVE; CYCLOSERINE; FLUPHENAZINE; GLUTAMIC ACID; GLYCINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; SCORING SYSTEM; SYMPTOMATOLOGY;

EID: 0029853426     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.153.12.1628     Document Type: Article

References (16)

1. Coyle JT: The glutamatergic dysfunction hypothesis for schizophrenia. Harvard Rev Psychiatry 1996; 3:241-253
2. Olney JW, Nuri NB: Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52:998-1007
3. Huettner JE: Competitive antagonism of glycine at the N-methyl-D-aspartate (NMDA) receptor. Biochem Pharmacol 1991; 41: 9-16
4. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH: D-Cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 1990; 510:158-160
5. Goff DC, Tsai G, Manoach DS, Coyle JT: A dose-finding trial of D-cycloserine added to neuroleptic for negative symptoms in schizophrenia. Am J Psychiatry 1995; 152:1213-1215
6. Emmett M, Mick S, Cler J: Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 1991; 30:1167-1171
7. Cascella NG, Macciardi F, Cavallini C, Smeraldi E: D-Cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label study. J Neural Transm 1994; 95: 105-111
8. Brunello N, Masotto C, Steardo L, Markstein R, Racagni G: New insights into the biology of schizophrenia through the mechanism of action of clozapine. Neuropsychopharmacology 1995; 13:177-213
9. Corbett R, Camacho F, Woods AT, Kerman LL, Fishkin RJ, Brooks K, Dunn RW: Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors. Psychopharmacology (Berl) 1995; 120:67-74
10. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT Jr: The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res 1989; 30: 119-123
11. Andreasen NC: Scale for the Assessment of Negative Symptoms (SANS). Iowa City, University of Iowa, 1983
12. Simpson GM, Angus JWS: A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212:11-19
13. Sternberg S: High-speed scanning in human memory. Science 1966; 153:652-654
14. Jones BN: Amino acids by o-phthaldialdehyde precolumn derivatization and reverse-phase HPLC, in Method of Protein Microcharacterization. Edited by Shively JE. Clifton, NJ, Humana Press, 1986, pp 121-151
15. McGale EHF, Pye IF, Stonier C, Hutchinson EC, Aber GM: Studies of the inter-relationship between cerebrospinal fluid and plasma amino acid concentrations in normal individuals. J Neurochem 1977; 29:291-297
16. Daly DA, Moghaddam B: Actions of clozapine and haloperidol on the extracellular levels of excitatory amino acids in the prefrontal cortex and striatum of conscious rats. Neurosci Lett 1993; 152:61-64